09/04/2026
Women deserve testosterone options designed for women. Period.
Right now, there is no FDA-approved testosterone product specifically formulated and dosed for women in the United States.
That matters.
It means women and their clinicians are often left trying to adapt products manufactured for men or use compounded formulations—while navigating inconsistent dosing, pharmacy barriers, cost, access, and a lack of standardized options.
On September 17, 2026, the FDA is holding a public meeting specifically focused on Testosterone Use in Menopausal Women, including the current evidence, safety, knowledge gaps, and potential future drug development.
But this isn’t only a conversation for researchers and regulators.
The FDA is asking for public comments—and that means your voice can be part of this conversation.
If you’re a woman who has struggled to access appropriate testosterone treatment, share your experience.
If you’re a healthcare provider who has encountered barriers prescribing testosterone for women, share what you’re seeing in clinical practice.
We need better research.
We need appropriate formulations and dosing for women.
We need safe, reliable, evidence-based options.
There is power in numbers.
Public comments are open through October 19, 2026.
Save this post. Share it with a friend or provider. And most importantly—submit a comment.
Women deserve better options. Let’s make sure the FDA hears us.
